Disentangling the Effect of Brain Insulin Resistance on Brain Health

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50-80
SponsorHenrik Bo Wiberg Larsson

About this trial

People with diabetes are at increased risk of developing dementia, including Alzheimer's disease and vascular dementia. In addition, persons with diabetes have more pronounced age-related brain atrophy and cognitive difficulties compared to people without diabetes. The mechanisms behind the effects on the brain of diabetes are still unclear. New research suggests that the brains of some people with diabetes do not respond normally to insulin signals, a condition known as brain insulin resistance (BIR). To date, there have been no large clinical studies investigating BIR and its impact on brain health, but several smaller studies suggest that BIR may be a cause of cognitive decline and impaired brain health in people with diabetes. Another mechanism that may contribute to impaired brain health in people with diabetes is damage to the blood vessels in the brain. Damage to blood vessels is a well-known complication of diabetes, but how it affects the brain is not fully described. In this project, we will investigate the relationship between BIR and brain blood vessel dysfunction and its relationship to cognition and brain function. This is done by examining patients with type 1 diabetes (T1D), type 2 diabetes (T2D) and healthy controls. The participants will undergo MRI brain scans to assess the impact of BIR on the brain physiology and to evaluate brain blood vessel health. Participants will undergo comprehensive assessments of their cognitive abilities and thorough health examination.

Eligibility criteria

Qualifiers

age 50-80 years

Diagnosis of either type 1 diabetes or type 2 diabetes

Diabetes duration of ≥10 years for individuals with type 1 diabetes and ≥5 years for individuals with type 2 diabetes

Disqualifiers

HbA1c >100 mmol/mol

Other type of diabetes

Weight >140 Kg

Treatment with drugs that cannot be paused for 12 hours

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

150 Participants
are grouped into 3 trial groups

Sponsors and collaborators

Henrik Bo Wiberg Larsson

Lead sponsor

Rigshospitalet, Denmark

Sponsor institution

Steno Diabetes Center Copenhagen

Collaborator

University of Ulm

Collaborator